Listar por autor "Alvarenga, Marco Papais"
Mostrando ítems 1-2 de 2
-
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months
Oliver-Martos, Begoña
; Fernández Fernández, Óscar; Órpez, Teresa; Alvarenga, Marcos Papais; Pinto-Medel, Mª Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández Sánchez, Victoria Eugenia; Leyva-Fernández, Laura[et al.] (SAGE Journals, 2011)
Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing–remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that ... -
Kinetics and incidence of anti-natalizumab antibodies in multiple sclerosis patients on treatment for 18 months.
Oliver-Martos, Begoña; Fernández, Óscar; Orpez, Teresa; Alvarenga, Marco Papais; Pinto-Medel, María Jesús; Guerrero, Miguel; León, Antonio; López-Madrona, José Carlos; Maldonado-Sánchez, Rafael; García-León, Juan Antonio; Luque, Gloria; Fernández, Victoria; Leyva-Fernández, Laura[et al.] (SAGE, 2011-03)
Natalizumab is a monoclonal antibody shown to be highly effective in the treatment of relapsing-remitting multiple sclerosis (RRMS). Patients treated with natalizumab can develop antibodies directed against this agent that ...